Dasatinib in chronic myelogenous leukemia

N Engl J Med. 2006 Sep 7;355(10):1062; author reply 1063-4. doi: 10.1056/NEJMc061882.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Dasatinib
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Paracentesis
  • Pleural Effusion / chemically induced*
  • Pleurodesis
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrimidines / adverse effects*
  • Thiazoles / adverse effects*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Dasatinib